Hikma制药公司的收入在H1 2025年增长6%至1.66B,尽管营业利润下降。 Hikma Pharmaceuticals saw revenue rise 6% to $1.66B in H1 2025, despite a drop in operating profit.

Hikma制药公司报告说,2025年上半年收入增长了6%,达到16.6亿美元,尽管由于产品组合的变化,核心运营利润下降了7%。 Hikma Pharmaceuticals reported a 6% rise in revenue to $1.66 billion for the first half of 2025, despite a 7% drop in core operating profit due to changes in product mix. 该公司保持了4-6%收入增长的全年指导,核心业务利润范围不变,为7.3亿至7.7亿美元。 The company maintained its full-year guidance for 4-6% revenue growth and an unchanged core operating profit range of $730 million to $770 million. Hikma的首席执行官预计,在强劲需求和新产品推出的支持下,下半年将恢复增长。 Hikma's CEO expects a return to growth in the second half of the year, supported by strong demand and new product launches.